Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
BRITISH JOURNAL OF HAEMATOLOGY（2020）
关键词
acute myeloid leukemia,myelodysplastic syndromes,refractory disease,clinical trial,phase I,anti-vascular
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要